Piper Jaffray downgraded BioCryst Pharma (NASDAQ: BCRX) from Overweight to Neutral with a price target of $5.00 (from $15.00) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE